2106-49-2

Usage

Uses

Used in Pharmaceutical Industry:
3-CHLORO-2-FLUORONITROBENZENE is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique molecular structure allows for the development of new medications with specific therapeutic properties, contributing to the advancement of pharmaceutical research and drug discovery.
Used in Agrochemical Industry:
In the agrochemical industry, 3-CHLORO-2-FLUORONITROBENZENE serves as an intermediate for the production of pesticides and other agrochemicals. Its incorporation into these products helps improve their effectiveness in protecting crops from pests and diseases, ensuring increased agricultural productivity and food security.
Used in Chemical Synthesis:
3-CHLORO-2-FLUORONITROBENZENE is also utilized as an intermediate in the synthesis of various chemicals and materials. Its unique functional groups enable the creation of a diverse range of compounds with different properties and applications, making it a valuable component in the chemical industry.

InChI:InChI=1S/C6H3ClFNO2/c7-4-2-1-3-5(6(4)8)9(10)11/h1-3H

Upstream product

• 3209-22-1 1,2-Dichloro-3-nitrobenzene 
• 611-06-3 2,4-dichloronitrobenzene 
• 95-50-1 1,2-dichloro-benzene 
• 3115-68-2 tetrabutyl phosphonium bromide 
• 64-20-0 tetramethylammonium bromide 

Downstream Products

• 2106-04-9 3-chloro-2-fluoroaniline 
• 345203-23-8 [(2-chloro-6-nitrophenylamino)methyl]phosphonic acid diethyl ester 
• 345203-24-9 [(2-amin-6-chlorophenylamino)methyl]phosphonic acid diethyl ester 
• 1026514-30-6 2-benzyloxycarbonylamino-3-[7-chloro-1-(diethoxy-phosphorylmethyl)-1H-benzoimidazol-2-yl]-propionic acid benzyl ester 
• 345203-25-0 [R(-)]-2-benzyloxycarbonylamino-N-{2-chloro-6-[(diethoxy-phosphorylmethyl)-amino]-phenyl}-succinamic acid benzyl ester 
• 75438-12-9 N-methyl-2-chloro-6-nitroaniline 
• 1352874-46-4 (4-bromo-phenyl)-(2-chloro-6-nitro-phenyl)-amine 
• 1248906-80-0 2-chloro-N-(3-methoxypropyl)-6-nitroaniline 
• 1365884-63-4 (R)-tert-Butyl 3-(3-chloro-2-(3-methoxypropylamino)phen ylcarbamoyl)piperidine-1-carboxylate 
• 1365884-67-8 tert-butyl (R)-1-(4-bromophenyl)-4-((R)-3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate 
• 1365884-68-9 tert-butyl (R)-1-(biphenyl-4-yl)-4-((R)-3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate 
• 1094360-61-8 6-chloro-N₁-(3-methoxypropyl)benzene-1,2-diamine 
• 1365884-69-0 (R)-3-amino-4-(biphenyl-4-yl)-1-((R)-3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one trifluoroacetate 
• 1393176-40-3 (S)-1-(7-chloro-1-phenyl-1H-benzoimidazol-2-yl)ethylamine 

Relevant academic research and scientific papers

An Efficient Second-Generation Manufacturing Process for the pan-RAF Inhibitor Belvarafenib

Herein, the development of a streamlined manufacturing process for the pan-RAF inhibitor belvarafenib (GDC-5573) is reported. The process to belvarafenib features a number of efficient key reactions, including a robust and scalable Pd-catalyzed carbonylation reaction to generate thienopyrimidine 2 and a highly chemoselective Pt/V/C-catalyzed nitro group reduction to access the penultimate intermediate 3. The final amide coupling was accomplished by a mild and safe protocol employing N,N,N′,N′-tetramethylchloroformamidinium hexafluorophosphate as the coupling reagent, which afforded belvarafenib on a multikilogram production scale after recrystallization.

O-dichlorobenzene with a quinolone drugs for coproduction method of key intermediate

The invention relates to the field of methods for preparing medicinal intermediates, in particular to the field of methods for preparing key intermediates of quinolone medicines, and develops a method for coproducing the key intermediates of the quinolone medicines by using o-dichlorobenzene as a raw material. The method comprises the following steps of: nitrifying the o-dichlorobenzene serving as the raw material, and performing distillation, purification and stepwise crystallization to obtain 2,3-dichloronitrobenzene and 3,4-dichloronitrobenzene; performing fluoridation on the 2,3-dichloronitrobenzene to obtain 3-chloro-2-fluoronitrobenzene, performing chlorination to obtain 2,6-dichlorofluorobenzene, performing nitration to obtain 1,3-dichloro-2-fluoro-4-nitrobenzene, and finally performing fluoridation to obtain 2,3,4-trifluoronitrobenzene; and performing fluoridation on the 2,3,4-trifluoronitrobenzene to obtain 3-chloro-4-fluoronitrobenzene, performing chlorination to obtain 1,3-dichloro-4-fluorobenzene, and finally performing acylation reaction on the 1,3-dichloro-4-fluorobenzene and acetylchloride to obtain 2,4-dichloro-5-fluoroacetophenone.

Design, synthesis, SAR, and biological evaluation of highly potent benzimidazole-spaced phosphono-α-amino acid competitive NMDA antagonists of the AP-6 type

A series of 2-amino-(phosphonoalkyl)-1H-benzimidazole-2-alkanoic acids was synthesized and evaluated for NMDA receptor affinity using a [3H]CPP binding assay. Functional antagonism of the NMDA receptor complex was evaluated in vitro using a stimulated [3H]TCP binding assay and in vivo by employing an NMDA-induced seizure model. Several compounds of the AP-6 type demonstrated potent and selective NMDA antagonistic activity both in vitro and in vivo. In particular, [R(-)]-2-amino-3-(5-chloro-1-phosphonomethyl-1H-benzoimidazol-2-yl)-propionic acid (1) displayed an IC50 value of 7.1 nM in the [3H]CPP binding assay and an ED50 value of 0.13 mg/kg (ip) in the NMDA lethality model. Compound 1, when administered intravenously as a single bolus dose of 3 mg/kg following permanent occlusion of the middle cerebral artery in the rat, reduced the volume of infarcted brain tissue by 45%. These results support a promising therapeutic potential for compound 1 as a neuroprotective agent.

Process for the preparation of chlorofluronitrobenzenes and difluoronitrobenzenes

A process for the preparation of chlorofluoronitrobenzenes and difluoronitrobenzenes, which comprises heating dichloronitrobenzene to not more than 200° C. in excess with an alkali metal fluoride having a total water content of about 0.2 to about 2.5% by weight in the presence of a quaternary ammonium and/or phosphonium salt, crown ether and/or polyethylene glycol dimethyl ether as catalyst in the absence of a solvent.

Process for preparing fluoronitrobenzenes

Fluoronitrobenzenes are prepared in an advantageous way from the corresponding chloronitrobenzenes and an alkali metal fluoride by means of a chlorine-fluorine exchange reaction with replacement of a chlorine atom by a fluorine atom, by catalyzing the reaction with a quaternaryammonium compound which comprises at least one alkoxypolyoxyalkyl radical.

Process for the synthesis of fluorinated derivatives

A process for the synthesis of fluorinated organic compounds and a reagent suitable for use in the process. The process is carried out by exchange with fluorides, while preferably agitating the reaction medium with ultrasonic sound.

Preparation of fluoroaromatic compounds in dispersion of potassium fluoride

An improved process is disclosed for preparing fluoroaromatic compounds (such as fluoronitrobenzene compounds) wherein chloroaromatic compounds (such as chloronitrobenzene compounds) are reacted with potassium fluoride in a solvent dispersion thereof prepared from a mixture including the solvent, the fluoride, methanol and an aromatic compound.